Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy
Authors
Keywords
-
Journal
OncoImmunology
Volume 5, Issue 9, Pages e1213934
Publisher
Informa UK Limited
Online
2016-07-23
DOI
10.1080/2162402x.2016.1213934
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
- (2016) Y. Lou et al. CLINICAL CANCER RESEARCH
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
- (2016) Takaaki Tokito et al. EUROPEAN JOURNAL OF CANCER
- Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
- (2016) Takehito Shukuya et al. Journal of Thoracic Oncology
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
- (2016) Marius Ilie et al. VIRCHOWS ARCHIV
- Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
- (2016) Jin Sheng et al. Scientific Reports
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
- (2015) A. S. Mansfield et al. CLINICAL CANCER RESEARCH
- Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
- (2015) V. K. Anagnostou et al. CLINICAL CANCER RESEARCH
- PD-L1 expression in small cell neuroendocrine carcinomas
- (2015) Anne M. Schultheis et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
- (2015) Moon-Young Kim et al. LUNG CANCER
- Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells
- (2015) Abdullah Alsuliman et al. Molecular Cancer
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Toward understanding and exploiting tumor heterogeneity
- (2015) Ash A Alizadeh et al. NATURE MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
- (2015) M. Callea et al. Cancer Immunology Research
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes
- (2013) D J Pinato et al. BRITISH JOURNAL OF CANCER
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More